MUC1 and breast neoplasm: The CTLs induced by these glycosylated and heteroclitic peptides reacted against the naturally glycosylated MUC1 on human breast tumor cells, suggesting that these analog peptides may be significantly better at inducing immune responses than the native antigen and could offer substantial improvements in the design of epitope-based vaccines, thus fulfilling MUC1’s potential as a therapeutic target.